Heron Therapeutics (HRTX) announced it received a notice from Nasdaq for failing to maintain the minimum $1.00 per share bid price requirement for continued listing. The company's stock traded below this threshold for 30 consecutive business days. The notice has no immediate effect on the listing or trading of the company's common stock.
Key Details
- Reason for Notice: The closing bid price of the company's common stock was below $1.00 per share from May 12, 2026, to June 24, 2026, violating Nasdaq Listing Rule 5550(a)(2).
- Compliance Period: The company has been granted a 180-calendar day grace period, until December 22, 2026, to regain compliance.
- Path to Compliance: To cure the deficiency, the stock's closing bid price must be at or above $1.00 for a minimum of ten consecutive business days within the compliance period. The company is currently exploring its options.